Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : KM023
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Preclinical
Sponsor : BRM Group
Deal Size : $23.0 million
Deal Type : Series A Financing
Kamari Pharma Announces Closing of $23 Million Financing
Details : Proceeds will be used to advance Kamari's lead program KM023, a first-in-class oral TRPV3 inhibitor, for three rare genetic skin diseases, Olmsted syndrome, severe keratoderma and ichthyosis.
Product Name : KM023
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 03, 2025
Lead Product(s) : KM023
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Sponsor : BRM Group
Deal Size : $23.0 million
Deal Type : Series A Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : GIBF2
Deal Size : $8.0 million
Deal Type : Financing
Kamari Pharma Raises $8 Million from the Sino-Israeli GIBF2 Fund
Details : The company develops topical and oral drugs based on proprietary small molecules that inhibit an ion channel designated TRPV3. These drugs are intended for the treatment of various dermatological diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 19, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : GIBF2
Deal Size : $8.0 million
Deal Type : Financing
Reset All
